Mirrx Therapeutics
Mirrx Therapeutics A/S secures seed financing for development of novel microRNA- blocking technology
Published in Gene Therapy Weekly, February 18th, 2010
Mirrx Therapeutics announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking "Blockmir" technology, as well as to strengthen its intellectual property portfolio. Blockmirs are antisense oligonucleotides that bind to a microRNA binding site on an mRNA, blocking specific unwanted microRNA:mRNA interactions without interfering with normal cellular function. SEED Capital, Inventure Capital and Vecata Invest participated in the financing round.
Explaining the rationale for the company's novel approach to targeting microRNA pathways, founder and Chief Scientific Officer Dr. Thorleif Moller...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-02-18)
More Articles from Gene Therapy Weekly
- Alzheimer Disease
Study results from University of Rochester in the area of Alzheimer disease published - Angiogenesis
New findings from INSERM describe advances in angiogenesis - Angiogenesis
Research results from Virginia Commonwealth University, Medical Department update knowledge of angiogenesis - Apoptosis
New apoptosis findings from Shandong University described - Assisted Suicide
New assisted suicide findings from T. Hussain and co-authors described - Asthma
Researchers at Huazhong University of Science & Technology have published new data on asthma - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
